opioid settlement funds
Coverage of opioid settlement funds in the Nexus archive.
- Controversial program paying drug users for used syringes becomes permanent in NYC
New York City has made the Community Syringe Redemption Program permanent, funding it with $3 million to pay participants up to $10 a day for returning used syringes. Critics argue the program diverts opioid settlement funds from addiction treatment, while city officials highlight its success in collecting over 2.3 million syringes since its 2025 launch.
- Controversial program paying drug users for used syringes becomes permanent in NYC
New York City has made the Community Syringe Redemption Program permanent, funding it with $3 million from opioid settlement funds. Critics argue the program gives money to addicts instead of treatment, while supporters highlight its success in collecting over 2.3 million syringes since 2025.
- Opioid settlement funds support prevention, treatment and outreach programs in Hampton Roads
Hampton Roads communities are allocating opioid settlement funds to support prevention, treatment, and outreach programs, addressing gaps in care beyond treatment beds as noted by local officials.
- June 16: Opiod Settlement Distribution; Nashville General Hospital CEO Candidates
A Metro audit revealed insufficient transparency and accountability in opioid settlement fund usage in Nashville, with managers interfering in reviews. The Nashville General Hospital CEO search has narrowed to two finalists: interim CEO Veronica Elders and former Yale New Haven Health Hospital president Keith Churchwell.
- Michigan drug deaths drop, but lawmakers question disjointed opioid efforts
Michigan drug deaths have decreased, but lawmakers are raising concerns about the allocation of opioid settlement funds. Lawmakers expressed worries over how these funds are being spent.
- GOP bill would use opioid funds to jump-start clinical trials on psychedelic-based trauma treatment
A Republican state Rep. Jaime Green proposes using opioid settlement funds to conduct clinical trials on ibogaine, a Schedule 1 psychedelic drug, to treat addiction and trauma disorders. The bill, House Bill 6020, aims to allocate $50 million for research through a consortium involving states, manufacturers, and universities.